01Clinical context
What is the rationale?
A defined rationale, medicines, organ function, previous reactions and proportionate alternatives are reviewed.
NAD+ Infusion · IV Supportive Treatments · Istanbul
NAD+ Infusion · IV Supportive Treatments · Istanbul
NAD+ Infusion
NAD+ biochemistry, oral supplements and IV NAD+ do not share one clinical evidence base. A named care method, ingredient or infusion is not a diagnosis and does not establish personal suitability.
Online information cannot diagnose, select an IV product, formula, dose, rate or laboratory protocol, or promise an outcome. Final decisions require an in-person medical assessment.
Clinical Orientation
Finding · identity · evidence · safety
Four questions precede a personal plan.
The sequence prevents a category name from becoming an automatic treatment recommendation.
02Identity
What exactly is proposed?
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
03Evidence
What does the evidence support?
Clinical evidence for IV NAD+ remains limited and does not support guaranteed energy, cognition, addiction treatment, longevity or cellular restoration.
04Safety
When should it stop?
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
Meaning and Boundary
Intravenous is a route, not a benefit
The category name does not determine the clinical decision.
NAD+ biochemistry, oral supplements and IV NAD+ do not share one clinical evidence base.
What assessment may do
- Clarify a limited clinical aim
- Identify the exact method or product
- Compare risks and alternatives
- Set follow-up and stopping criteria
What must not be assumed
- Guarantee suitability or benefit
- Treat IV delivery as automatically superior to oral care
- Create a public personal protocol
- Promise permanence, prevention or a general wellness effect
No energy, cognitive, addiction, longevity, anti-ageing or cellular-renewal guarantee is made.
Medical Suitability
Rationale and organ context before venous access
Five checks come before selection.
History, examination, current treatment, contraindications and a proportionate alternative are reviewed together.
- 01
Clarify the problem
A defined rationale, medicines, organ function, previous reactions and proportionate alternatives are reviewed.
- 02
Review current treatment
Medicines, allergies, previous procedures or infusions and relevant reactions are considered.
- 03
Identify the exact option
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
- 04
Compare alternatives
No infusion, diagnosis-led evaluation, nutrition, sleep or other established care as appropriate
- 05
Plan follow-up
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
Infusion Safety Path
Before · during · after
Safety depends on a complete, documented chain.
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
01Before
Confirm rationale and product identity
A defined rationale, medicines, organ function, previous reactions and proportionate alternatives are reviewed.
- Review history and examination
- Check contraindications
- Keep alternatives open
02During
Control preparation and administration
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
- Maintain traceability
- Monitor tolerance
- Stop when safety changes
03After
Separate expected response from harm
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
- Record observations
- Explain warning signs
- Provide a review route
No public mixture formula, dose, dilution, rate, volume, laboratory panel or infusion schedule is provided.
Evidence and Limits
Method-, product- and indication-specific
Biology or popularity is not proof of clinical benefit.
Clinical evidence for IV NAD+ remains limited and does not support guaranteed energy, cognition, addiction treatment, longevity or cellular restoration.
Keep the indication exact
Evidence in one diagnosis or deficiency does not establish a general effect.
Keep the intervention exact
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
Keep endpoints separate
Symptoms, photographs, laboratory values and patient-reported outcomes are not interchangeable.
Retain uncertainty
No energy, cognitive, addiction, longevity, anti-ageing or cellular-renewal guarantee is made.
Manufacturer information may identify a product and instructions, but it is not treated as independent evidence of a general class effect.
Individual Plan
Reason · option · review · exit
Personalisation means tighter decisions, not unlimited combinations.
A plan remains limited to a defined question and can conclude that no procedure or infusion is appropriate.
Name the reason
A defined rationale, medicines, organ function, previous reactions and proportionate alternatives are reviewed.
Name the option
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
Name the endpoint
Agree what would count as a meaningful and measurable change.
Name the exit
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
Course and Follow-Up
Expected response · complication · reassessment
Repetition is never automatic.
Tolerance and the agreed clinical endpoint are reviewed separately before any further intervention.
- 01Before
Baseline
Record the starting clinical context and intended endpoint.
- 02Same day
Immediate review
Observe tolerance and unexpected reactions.
- 03Later
Clinical review
Compare the relevant finding without automatic attribution.
- 04Decision
Continue, change or stop
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
Risks and Alternatives
Common, serious and delayed harm
Risk remains visible even when a treatment is described as supportive.
Nausea, headache, flushing, cramping, chest discomfort, vein complications and infusion reactions may occur.
01Safety
Recognised harms
Nausea, headache, flushing, cramping, chest discomfort, vein complications and infusion reactions may occur.
02Options
Alternatives
No infusion, diagnosis-led evaluation, nutrition, sleep or other established care as appropriate
03Action
Escalation
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Treatment is withheld when diagnosis or rationale, product identity, consent, safety controls or follow-up is inadequate. Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
Istanbul and Follow-Up
Assessment and review must travel together
International care needs a workable safety route.
Travel does not shorten observation or remove the need for local medical access.
01Before travel
Organise the question
History and existing records prepare discussion without confirming treatment.
02In Istanbul
Assess in person
A defined rationale, medicines, organ function, previous reactions and proportionate alternatives are reviewed.
03Treatment day
Keep exact records
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
04After return
Plan escalation
Stop for chest symptoms, breathing difficulty, severe nausea, neurological symptoms, swelling or a significant infusion-site reaction.
The Doctor Aslan Approach
Clinical question before treatment label
Selection follows diagnosis, identity, evidence and safety.
Doctor Aslan keeps the clinical question, exact intervention, realistic limits, alternatives and follow-up in the same decision.
Assess first
A defined rationale, medicines, organ function, previous reactions and proportionate alternatives are reviewed.
Verify identity
Product identity, manufacture, purity, stability, licence, compatibility and sterile administration must be established.
Limit the claim
No energy, cognitive, addiction, longevity, anti-ageing or cellular-renewal guarantee is made.
Accept no treatment
Observation or another established pathway may be the safer choice.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about NAD+ Infusion; no personal prescription or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is NAD+ Infusion?+
NAD+ Infusion is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for NAD+ Infusion?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Define the question · verify the option · compare alternatives